| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 26 | 2023 | 567 | 3.660 |
Why?
|
| Bortezomib | 19 | 2024 | 71 | 2.640 |
Why?
|
| Leukemia | 12 | 2020 | 379 | 2.070 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 12 | 2024 | 92 | 1.970 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12 | 2022 | 811 | 1.760 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2024 | 1356 | 1.610 |
Why?
|
| Antineoplastic Agents | 11 | 2021 | 1854 | 1.590 |
Why?
|
| Boronic Acids | 8 | 2015 | 48 | 1.320 |
Why?
|
| Hodgkin Disease | 9 | 2023 | 298 | 1.300 |
Why?
|
| Pyrazines | 8 | 2015 | 73 | 1.290 |
Why?
|
| Protein Array Analysis | 5 | 2023 | 107 | 0.990 |
Why?
|
| Cyclopentanes | 2 | 2023 | 22 | 0.930 |
Why?
|
| Enzyme Inhibitors | 2 | 2021 | 609 | 0.830 |
Why?
|
| Pyrimidines | 2 | 2023 | 418 | 0.740 |
Why?
|
| Child | 52 | 2024 | 25843 | 0.710 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2021 | 21 | 0.710 |
Why?
|
| NF-kappa B | 4 | 2021 | 482 | 0.700 |
Why?
|
| Proteins | 6 | 2023 | 1098 | 0.700 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2021 | 825 | 0.690 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2022 | 1317 | 0.670 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2010 | 104 | 0.660 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 5 | 2020 | 182 | 0.640 |
Why?
|
| Dacarbazine | 3 | 2013 | 99 | 0.610 |
Why?
|
| Gene Expression Profiling | 5 | 2022 | 1922 | 0.590 |
Why?
|
| Cytarabine | 6 | 2023 | 100 | 0.580 |
Why?
|
| Child, Preschool | 30 | 2024 | 14838 | 0.580 |
Why?
|
| Medical Oncology | 4 | 2017 | 247 | 0.550 |
Why?
|
| Apoptosis | 7 | 2021 | 1945 | 0.550 |
Why?
|
| Infant | 24 | 2024 | 13201 | 0.520 |
Why?
|
| Neuroblastoma | 1 | 2021 | 550 | 0.490 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2022 | 128 | 0.480 |
Why?
|
| Program Evaluation | 2 | 2017 | 457 | 0.480 |
Why?
|
| Proteomics | 6 | 2022 | 598 | 0.470 |
Why?
|
| Humans | 85 | 2024 | 134085 | 0.470 |
Why?
|
| Adolescent | 31 | 2024 | 20601 | 0.440 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 168 | 0.430 |
Why?
|
| Bone Resorption | 1 | 2013 | 52 | 0.400 |
Why?
|
| Mentors | 2 | 2017 | 160 | 0.400 |
Why?
|
| Disease-Free Survival | 6 | 2024 | 972 | 0.380 |
Why?
|
| Benzimidazoles | 2 | 2009 | 136 | 0.370 |
Why?
|
| Neoplasm, Residual | 2 | 2024 | 134 | 0.360 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 624 | 0.350 |
Why?
|
| Cell Line, Tumor | 12 | 2021 | 3797 | 0.350 |
Why?
|
| Tumor Microenvironment | 4 | 2024 | 699 | 0.340 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2008 | 111 | 0.340 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2009 | 36 | 0.330 |
Why?
|
| Bone Marrow | 3 | 2021 | 336 | 0.330 |
Why?
|
| Prognosis | 13 | 2024 | 5085 | 0.330 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2011 | 197 | 0.330 |
Why?
|
| Proteasome Inhibitors | 4 | 2016 | 66 | 0.320 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 294 | 0.320 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2009 | 21 | 0.320 |
Why?
|
| Male | 42 | 2024 | 66057 | 0.320 |
Why?
|
| Female | 42 | 2024 | 71851 | 0.290 |
Why?
|
| DNA, Mitochondrial | 5 | 1996 | 244 | 0.290 |
Why?
|
| Clinical Trials as Topic | 4 | 2016 | 1157 | 0.290 |
Why?
|
| Extracellular Vesicles | 2 | 2019 | 55 | 0.290 |
Why?
|
| Glucocorticoids | 3 | 2022 | 402 | 0.280 |
Why?
|
| Pediatrics | 3 | 2017 | 1215 | 0.270 |
Why?
|
| Signal Transduction | 8 | 2024 | 4934 | 0.270 |
Why?
|
| Proteasome Endopeptidase Complex | 3 | 2016 | 276 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2014 | 1741 | 0.270 |
Why?
|
| Paclitaxel | 1 | 2008 | 143 | 0.270 |
Why?
|
| Recurrence | 7 | 2022 | 1472 | 0.270 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1612 | 0.260 |
Why?
|
| Lymphoma | 2 | 2022 | 335 | 0.260 |
Why?
|
| Neoplasm Proteins | 3 | 2018 | 717 | 0.260 |
Why?
|
| Animals | 25 | 2024 | 36543 | 0.260 |
Why?
|
| Maximum Tolerated Dose | 6 | 2013 | 174 | 0.260 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2017 | 67 | 0.250 |
Why?
|
| Mice | 18 | 2023 | 19044 | 0.230 |
Why?
|
| Protease Inhibitors | 1 | 2005 | 100 | 0.230 |
Why?
|
| Models, Biological | 4 | 2022 | 1540 | 0.230 |
Why?
|
| Thiophenes | 1 | 2005 | 72 | 0.230 |
Why?
|
| Etoposide | 3 | 2022 | 120 | 0.220 |
Why?
|
| Interleukin-7 | 3 | 2022 | 50 | 0.220 |
Why?
|
| Neoplasms | 4 | 2017 | 3037 | 0.220 |
Why?
|
| Adult | 18 | 2024 | 31964 | 0.220 |
Why?
|
| Focal Adhesion Kinase 2 | 1 | 2023 | 10 | 0.220 |
Why?
|
| Quinazolines | 1 | 2005 | 184 | 0.220 |
Why?
|
| Reed-Sternberg Cells | 1 | 2023 | 7 | 0.210 |
Why?
|
| Adenoviridae | 5 | 1993 | 610 | 0.200 |
Why?
|
| SEC Translocation Channels | 1 | 2022 | 5 | 0.190 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2003 | 57 | 0.190 |
Why?
|
| Stem Cell Niche | 2 | 2019 | 58 | 0.190 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2022 | 703 | 0.190 |
Why?
|
| Point Mutation | 2 | 2021 | 361 | 0.190 |
Why?
|
| Transcription Factor RelA | 1 | 2021 | 57 | 0.180 |
Why?
|
| NEDD8 Protein | 1 | 2021 | 12 | 0.180 |
Why?
|
| Young Adult | 9 | 2024 | 9917 | 0.180 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 177 | 0.180 |
Why?
|
| Phosphorylation | 2 | 2023 | 1712 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2022 | 128 | 0.180 |
Why?
|
| Interleukin-10 | 1 | 2022 | 191 | 0.180 |
Why?
|
| Oxidative Phosphorylation | 4 | 2019 | 131 | 0.170 |
Why?
|
| Thymocytes | 1 | 2020 | 9 | 0.170 |
Why?
|
| Atovaquone | 1 | 2019 | 10 | 0.160 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 146 | 0.160 |
Why?
|
| Specimen Handling | 1 | 2020 | 148 | 0.160 |
Why?
|
| Myeloid Cells | 1 | 2020 | 123 | 0.160 |
Why?
|
| Cell Communication | 1 | 2020 | 188 | 0.160 |
Why?
|
| MicroRNAs | 3 | 2021 | 951 | 0.150 |
Why?
|
| Peptide Hydrolases | 1 | 2020 | 149 | 0.150 |
Why?
|
| T-Lymphocytes | 5 | 2023 | 1814 | 0.150 |
Why?
|
| Metabolome | 1 | 2021 | 312 | 0.150 |
Why?
|
| Bcl-2-Like Protein 11 | 2 | 2017 | 13 | 0.150 |
Why?
|
| Histones | 2 | 2021 | 573 | 0.150 |
Why?
|
| Cell Cycle Proteins | 1 | 2023 | 707 | 0.150 |
Why?
|
| Sequence Deletion | 3 | 1996 | 538 | 0.150 |
Why?
|
| Cell Cycle | 1 | 2021 | 627 | 0.150 |
Why?
|
| Salvage Therapy | 2 | 2014 | 202 | 0.150 |
Why?
|
| Treatment Outcome | 10 | 2022 | 13051 | 0.150 |
Why?
|
| Survival Rate | 3 | 2021 | 2218 | 0.150 |
Why?
|
| Immunoconjugates | 1 | 2018 | 46 | 0.140 |
Why?
|
| Deoxycytidine | 1 | 2018 | 84 | 0.140 |
Why?
|
| Azacitidine | 2 | 2023 | 53 | 0.140 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2018 | 17 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 796 | 0.140 |
Why?
|
| Metabolomics | 1 | 2021 | 458 | 0.140 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2018 | 130 | 0.140 |
Why?
|
| Infant, Newborn | 6 | 2018 | 8607 | 0.140 |
Why?
|
| Mice, Inbred NOD | 4 | 2020 | 318 | 0.140 |
Why?
|
| Oncologists | 1 | 2017 | 31 | 0.140 |
Why?
|
| Biomarkers | 3 | 2021 | 3433 | 0.140 |
Why?
|
| Osteogenesis | 1 | 2018 | 168 | 0.140 |
Why?
|
| STAT Transcription Factors | 1 | 2017 | 25 | 0.140 |
Why?
|
| Janus Kinases | 1 | 2017 | 33 | 0.140 |
Why?
|
| Myristoylated Alanine-Rich C Kinase Substrate | 1 | 2016 | 1 | 0.130 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2016 | 12 | 0.130 |
Why?
|
| Personal Satisfaction | 2 | 2017 | 106 | 0.130 |
Why?
|
| Mice, SCID | 4 | 2020 | 615 | 0.130 |
Why?
|
| Protein Subunits | 2 | 2016 | 174 | 0.130 |
Why?
|
| Pediatricians | 1 | 2017 | 71 | 0.130 |
Why?
|
| Oncogene Proteins, Viral | 3 | 1991 | 67 | 0.130 |
Why?
|
| Exocytosis | 1 | 2016 | 66 | 0.130 |
Why?
|
| Mentoring | 1 | 2017 | 82 | 0.130 |
Why?
|
| Aminoglycosides | 1 | 2016 | 46 | 0.120 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 1996 | 28 | 0.120 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 120 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2020 | 1012 | 0.120 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 433 | 0.120 |
Why?
|
| Ifosfamide | 1 | 2015 | 35 | 0.120 |
Why?
|
| Vinblastine | 1 | 2015 | 58 | 0.120 |
Why?
|
| DNA, Neoplasm | 1 | 1996 | 320 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2019 | 564 | 0.110 |
Why?
|
| Idarubicin | 1 | 2014 | 6 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 5 | 2016 | 1106 | 0.110 |
Why?
|
| Huntington Disease | 1 | 1995 | 146 | 0.110 |
Why?
|
| Time Factors | 4 | 2019 | 6604 | 0.110 |
Why?
|
| Gene Expression Regulation, Leukemic | 3 | 2021 | 69 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2018 | 2561 | 0.110 |
Why?
|
| Transcriptome | 1 | 2021 | 1137 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1996 | 253 | 0.100 |
Why?
|
| Rabbits | 1 | 2014 | 729 | 0.100 |
Why?
|
| Cerebral Cortex | 2 | 1995 | 483 | 0.100 |
Why?
|
| Chondrocytes | 1 | 2013 | 51 | 0.100 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2013 | 72 | 0.100 |
Why?
|
| DNA Repair Enzymes | 2 | 2013 | 48 | 0.090 |
Why?
|
| DNA Modification Methylases | 2 | 2013 | 52 | 0.090 |
Why?
|
| Radiation Dosage | 1 | 2012 | 147 | 0.090 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2011 | 47 | 0.090 |
Why?
|
| Metabolic Clearance Rate | 2 | 2009 | 145 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 1071 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2016 | 519 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 2 | 2011 | 407 | 0.090 |
Why?
|
| Kidney Neoplasms | 1 | 1996 | 461 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2016 | 556 | 0.090 |
Why?
|
| DNA Damage | 4 | 2023 | 547 | 0.090 |
Why?
|
| Metalloendopeptidases | 2 | 2020 | 102 | 0.090 |
Why?
|
| Cell Survival | 3 | 2019 | 890 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 1145 | 0.090 |
Why?
|
| Unfolded Protein Response | 2 | 2023 | 64 | 0.090 |
Why?
|
| Education, Continuing | 1 | 2010 | 30 | 0.090 |
Why?
|
| Immunoblotting | 2 | 2007 | 319 | 0.090 |
Why?
|
| Cell Differentiation | 1 | 2018 | 2043 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 399 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 311 | 0.080 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2009 | 90 | 0.080 |
Why?
|
| Nitrophenols | 1 | 2009 | 16 | 0.080 |
Why?
|
| DNA Mismatch Repair | 1 | 2009 | 54 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2010 | 179 | 0.080 |
Why?
|
| Biphenyl Compounds | 1 | 2009 | 63 | 0.080 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2009 | 88 | 0.080 |
Why?
|
| Career Choice | 1 | 2010 | 163 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2013 | 510 | 0.080 |
Why?
|
| Drug Synergism | 1 | 2009 | 242 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2007 | 867 | 0.080 |
Why?
|
| Transfection | 1 | 1991 | 1096 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2009 | 121 | 0.080 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 407 | 0.080 |
Why?
|
| Endopeptidases | 1 | 2009 | 119 | 0.080 |
Why?
|
| Cyclosporine | 1 | 2009 | 148 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2023 | 1255 | 0.070 |
Why?
|
| Central Nervous System Diseases | 1 | 2009 | 110 | 0.070 |
Why?
|
| Dexamethasone | 2 | 2022 | 281 | 0.070 |
Why?
|
| Viral Proteins | 1 | 1990 | 360 | 0.070 |
Why?
|
| Half-Life | 1 | 2008 | 162 | 0.070 |
Why?
|
| Microsatellite Instability | 1 | 2007 | 40 | 0.070 |
Why?
|
| Molecular Sequence Data | 6 | 1996 | 3979 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2009 | 287 | 0.070 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2009 | 147 | 0.070 |
Why?
|
| I-kappa B Kinase | 1 | 2007 | 62 | 0.070 |
Why?
|
| Base Sequence | 4 | 2011 | 3177 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2010 | 778 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 609 | 0.060 |
Why?
|
| Cytokines | 2 | 2022 | 1400 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2023 | 820 | 0.060 |
Why?
|
| Mitochondria | 3 | 2020 | 756 | 0.060 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2005 | 92 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2005 | 261 | 0.060 |
Why?
|
| Gallbladder Diseases | 1 | 2004 | 26 | 0.060 |
Why?
|
| Heat-Shock Proteins | 1 | 2005 | 204 | 0.060 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2011 | 894 | 0.060 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2004 | 44 | 0.060 |
Why?
|
| Computational Biology | 2 | 2021 | 888 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2196 | 0.050 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2023 | 26 | 0.050 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2023 | 26 | 0.050 |
Why?
|
| Physicians | 1 | 2010 | 638 | 0.050 |
Why?
|
| Valosin Containing Protein | 1 | 2023 | 14 | 0.050 |
Why?
|
| Vidarabine | 1 | 2023 | 78 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 572 | 0.050 |
Why?
|
| Discoidin Domain Receptors | 1 | 2023 | 3 | 0.050 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2003 | 10 | 0.050 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2003 | 10 | 0.050 |
Why?
|
| Integrins | 1 | 2023 | 103 | 0.050 |
Why?
|
| Paresis | 1 | 2003 | 35 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 1409 | 0.050 |
Why?
|
| Blood Component Transfusion | 1 | 2003 | 58 | 0.050 |
Why?
|
| Consciousness Disorders | 1 | 2003 | 26 | 0.050 |
Why?
|
| ADAMTS13 Protein | 1 | 2003 | 67 | 0.050 |
Why?
|
| ADAM Proteins | 1 | 2003 | 87 | 0.050 |
Why?
|
| Hydroxamic Acids | 2 | 2013 | 65 | 0.050 |
Why?
|
| Plasma | 1 | 2003 | 105 | 0.050 |
Why?
|
| Bleomycin | 1 | 2022 | 153 | 0.050 |
Why?
|
| Electron Transport Complex I | 1 | 2022 | 33 | 0.050 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2023 | 128 | 0.050 |
Why?
|
| Plasma Exchange | 1 | 2003 | 89 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 1996 | 1627 | 0.050 |
Why?
|
| Prednisone | 1 | 2022 | 289 | 0.050 |
Why?
|
| Vincristine | 1 | 2022 | 196 | 0.050 |
Why?
|
| Receptor, Notch1 | 1 | 2022 | 80 | 0.050 |
Why?
|
| Cell Line | 4 | 2009 | 2858 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2003 | 155 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 756 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2016 | 914 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2022 | 303 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2022 | 2136 | 0.040 |
Why?
|
| Meningitis, Aseptic | 1 | 2001 | 14 | 0.040 |
Why?
|
| Glutamine | 1 | 2022 | 222 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 2021 | 112 | 0.040 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 30 | 0.040 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2022 | 121 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2023 | 837 | 0.040 |
Why?
|
| Anemia, Sickle Cell | 1 | 2004 | 346 | 0.040 |
Why?
|
| Histone Code | 1 | 2021 | 53 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2003 | 279 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2022 | 426 | 0.040 |
Why?
|
| Electron Transport | 1 | 2020 | 57 | 0.040 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2020 | 96 | 0.040 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2020 | 21 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2022 | 451 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2019 | 4012 | 0.040 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2019 | 35 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2003 | 467 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2013 | 358 | 0.040 |
Why?
|
| Epigenomics | 1 | 2021 | 195 | 0.040 |
Why?
|
| Ribosomal Protein S6 | 1 | 2019 | 14 | 0.040 |
Why?
|
| STAT5 Transcription Factor | 1 | 2020 | 90 | 0.040 |
Why?
|
| Regulatory-Associated Protein of mTOR | 1 | 2019 | 12 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2023 | 710 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2021 | 384 | 0.040 |
Why?
|
| Electronic Health Records | 2 | 2017 | 796 | 0.040 |
Why?
|
| DNA Repair | 1 | 2023 | 635 | 0.040 |
Why?
|
| Remission Induction | 1 | 2020 | 310 | 0.040 |
Why?
|
| Age of Onset | 1 | 2021 | 637 | 0.040 |
Why?
|
| Reference Standards | 1 | 2020 | 247 | 0.040 |
Why?
|
| Monocytes | 1 | 2020 | 360 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 4877 | 0.040 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2019 | 141 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 1488 | 0.040 |
Why?
|
| Disease Progression | 1 | 2024 | 2264 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2021 | 626 | 0.040 |
Why?
|
| Canada | 1 | 2018 | 346 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 4806 | 0.030 |
Why?
|
| Adenovirus Early Proteins | 3 | 1991 | 4 | 0.030 |
Why?
|
| Career Mobility | 1 | 2017 | 54 | 0.030 |
Why?
|
| Middle Aged | 6 | 2021 | 29402 | 0.030 |
Why?
|
| Body Surface Area | 1 | 2017 | 35 | 0.030 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2017 | 27 | 0.030 |
Why?
|
| Immunoproteins | 1 | 2016 | 2 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2017 | 102 | 0.030 |
Why?
|
| Aging | 2 | 1995 | 1306 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2017 | 187 | 0.030 |
Why?
|
| Observer Variation | 1 | 2017 | 314 | 0.030 |
Why?
|
| Blood Specimen Collection | 1 | 2016 | 49 | 0.030 |
Why?
|
| Mutation | 4 | 2021 | 6305 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 958 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 710 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2016 | 185 | 0.030 |
Why?
|
| Ubiquitin | 1 | 2016 | 150 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2017 | 197 | 0.030 |
Why?
|
| RNA, Neoplasm | 1 | 1996 | 146 | 0.030 |
Why?
|
| Optic Atrophies, Hereditary | 1 | 1995 | 17 | 0.030 |
Why?
|
| Length of Stay | 2 | 2016 | 1389 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2019 | 3186 | 0.030 |
Why?
|
| Mitochondrial Myopathies | 1 | 1995 | 28 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1996 | 376 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 577 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2017 | 17518 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1995 | 373 | 0.030 |
Why?
|
| Genes, Viral | 2 | 1993 | 186 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2003 | 872 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2017 | 3999 | 0.030 |
Why?
|
| Adenine Nucleotides | 1 | 2014 | 42 | 0.030 |
Why?
|
| Acute Disease | 1 | 2017 | 1192 | 0.030 |
Why?
|
| Arabinonucleosides | 1 | 2014 | 33 | 0.030 |
Why?
|
| Texas | 1 | 2003 | 3715 | 0.030 |
Why?
|
| Mortality | 1 | 2016 | 262 | 0.030 |
Why?
|
| Age Factors | 2 | 2018 | 2997 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 398 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2021 | 1146 | 0.030 |
Why?
|
| Biological Evolution | 1 | 1995 | 256 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 1996 | 840 | 0.030 |
Why?
|
| Adenovirus E3 Proteins | 1 | 1993 | 3 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 3665 | 0.030 |
Why?
|
| Molecular Weight | 2 | 1991 | 388 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 1996 | 746 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 1995 | 2793 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 2666 | 0.020 |
Why?
|
| Biopsy | 1 | 2016 | 1303 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2021 | 5206 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2016 | 422 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2012 | 130 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2012 | 148 | 0.020 |
Why?
|
| Aged | 5 | 2021 | 21756 | 0.020 |
Why?
|
| Fibroblasts | 3 | 1991 | 925 | 0.020 |
Why?
|
| Neutropenia | 1 | 2013 | 204 | 0.020 |
Why?
|
| Cadmium | 1 | 1991 | 31 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 1991 | 56 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 1991 | 79 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2013 | 237 | 0.020 |
Why?
|
| Research | 1 | 2012 | 273 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 2539 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 1217 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2021 | 2729 | 0.020 |
Why?
|
| DNA Primers | 1 | 2011 | 672 | 0.020 |
Why?
|
| Lysogeny | 1 | 1990 | 11 | 0.020 |
Why?
|
| Cycloheximide | 1 | 1990 | 46 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 1761 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 3043 | 0.020 |
Why?
|
| Job Satisfaction | 1 | 2010 | 93 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 1990 | 123 | 0.020 |
Why?
|
| Serotyping | 1 | 1990 | 178 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 1990 | 99 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 295 | 0.020 |
Why?
|
| Epitopes | 1 | 2011 | 446 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 1721 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2009 | 32 | 0.020 |
Why?
|
| Metaphase | 1 | 2009 | 35 | 0.020 |
Why?
|
| Anaphase | 1 | 2009 | 13 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1736 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2009 | 60 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 1996 | 2911 | 0.020 |
Why?
|
| Xenopus laevis | 1 | 2009 | 129 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 65 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 1433 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1991 | 497 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2009 | 333 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1331 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2011 | 672 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2009 | 320 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 1187 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2009 | 116 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2009 | 649 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2009 | 513 | 0.020 |
Why?
|
| Piperazines | 1 | 2009 | 257 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 1357 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2009 | 727 | 0.020 |
Why?
|
| Caspase 8 | 1 | 2006 | 24 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2009 | 1140 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2009 | 459 | 0.020 |
Why?
|
| Alzheimer Disease | 1 | 1994 | 878 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 772 | 0.020 |
Why?
|
| Peptides | 1 | 2009 | 862 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2004 | 5477 | 0.010 |
Why?
|
| Pulse Therapy, Drug | 1 | 2004 | 9 | 0.010 |
Why?
|
| Liver Diseases | 1 | 2009 | 392 | 0.010 |
Why?
|
| Biological Availability | 1 | 2004 | 153 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 252 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 335 | 0.010 |
Why?
|
| Elective Surgical Procedures | 1 | 2004 | 170 | 0.010 |
Why?
|
| Tissue Distribution | 2 | 1994 | 402 | 0.010 |
Why?
|
| United States | 1 | 2018 | 11750 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 1343 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 1492 | 0.010 |
Why?
|
| Brain | 1 | 1992 | 3227 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2004 | 1004 | 0.010 |
Why?
|
| Risk Factors | 1 | 2012 | 11166 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 3854 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 3104 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2004 | 3729 | 0.010 |
Why?
|
| Putamen | 1 | 1994 | 21 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1995 | 300 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1995 | 673 | 0.010 |
Why?
|
| Viral Structural Proteins | 1 | 1993 | 48 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1993 | 328 | 0.010 |
Why?
|
| Cell Death | 1 | 1993 | 252 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 1994 | 7207 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1993 | 912 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1991 | 158 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1993 | 993 | 0.010 |
Why?
|
| Pedigree | 1 | 1995 | 1698 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1991 | 169 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1995 | 412 | 0.010 |
Why?
|
| RNA, Viral | 1 | 1993 | 563 | 0.010 |
Why?
|
| Cerebellum | 1 | 1994 | 464 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 1995 | 814 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1993 | 806 | 0.010 |
Why?
|